Richard Aranda
Chief Tech/Sci/R&D Officer bij GOSSAMER BIO, INC.
Vermogen: 280 307 $ op 29-02-2024
Profiel
Richard Aranda is Chief Medical Officer for Gossamer Bio, Inc.
In his past career Dr. Aranda held the position of Principal at Bristol Myers Squibb Co. and Vice President-Clinical Development at Receptos LLC (a subsidiary of Bristol Myers Squibb Co.) and Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc.
Richard Aranda received an undergraduate degree from the University of California, Santa Cruz and a doctorate from Stanford School of Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
GOSSAMER BIO, INC.
0.09% | 18-03-2024 | 198 799 ( 0.09% ) | 280 307 $ | 29-02-2024 |
Actieve functies van Richard Aranda
Bedrijven | Functie | Begin |
---|---|---|
GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01-06-2021 |
Eerdere bekende functies van Richard Aranda
Bedrijven | Functie | Einde |
---|---|---|
RECEPTOS INC | Corporate Officer/Principal | 01-01-2018 |
Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01-01-2015 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-05-2011 |
Opleiding van Richard Aranda
University of California, Santa Cruz | Undergraduate Degree |
Stanford School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GOSSAMER BIO, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Novo-Nordisk Biochem, Inc. |